Sugi Predict

Sugi Predict / Compounds / SCHEMBL371728

SCHEMBL371728

SCHEMBL371728

O=[N+]([O-])c1ccc(OCc2ccccc2)c(OCc2ccccc2)c1

nearest known ligand 0.70

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.70
▸ KMT2A Q03164 3/20 0.70
▸ MAPT P10636 1/20 0.70
▸ CYP19A1 P11511 11/20 0.65
▸ CYP11B1 P15538 2/20 0.65
▸ CYP11B2 P19099 2/20 0.65
▸ CTSV O60911 2/20 0.52
▸ CTSL P07711 2/20 0.52
▸ PPIA P62937 1/20 0.52
▸ CNR1 P21554 1/20 0.51
▸ ACHE P22303 1/20 0.51
▸ CNR2 P34972 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31418722 1.00 MEN1 (0.70) MEN1KMT2AMAPTCYP19A1CYP11B1
Bicarbonate SCHEMBL5503301 0.94 CYP19A1 (0.65) MEN1KMT2AMAPTCYP19A1CYP11B1
SCHEMBL30721937 0.91 MAPT (0.67) MEN1KMT2AMAPTCYP19A1CYP11B1
SCHEMBL30354869 0.91 MAPT (0.67) MEN1KMT2AMAPTCYP19A1CYP11B1
SCHEMBL5929724 0.91 MAPT (0.67) MEN1KMT2AMAPTCYP19A1CYP11B1
SCHEMBL2063456 0.91 MAPT (0.67) MEN1KMT2AMAPTCYP19A1CYP11B1
SCHEMBL6572912 0.90 CYP19A1 (0.62) MEN1KMT2AMAPTCYP19A1CYP11B1
SCHEMBL6573349 0.90 PTGDR2 (0.64) MEN1KMT2AMAPTCYP19A1CYP11B1
SCHEMBL7476491 0.90 PTGDR2 (0.64) MEN1KMT2AMAPTCYP19A1CYP11B1
SCHEMBL21295359 0.90 MEN1 (0.62) MEN1KMT2AMAPTCYP19A1CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023171231-A1 ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE キヤノン株式会社 2023-09-14 — — WO disclosed
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US disclosed
EP-3329918-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2018-06-06 — — EP disclosed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US disclosed
EP-2409704-B1 c-Met modulators and methods of use EXELIXIS INC (US) 2017-09-20 — — EP disclosed
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 — — US disclosed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
EP-1751097-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES Proteotech, Inc. (US) 2007-02-14 — — EP disclosed
US-20060199838-A1 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies PROTAMED, INC. 2006-09-07 — — US disclosed
EP-1673085-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2006-06-28 — — EP disclosed
WO-2005113489-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH, INC. (US) 2005-12-01 — — WO disclosed
WO-2005030140-A2 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-04-07 — — WO disclosed
US-5318963-A Heterocyclic hydrazide derivatives of monocyclic β-lactam antibiotics E. R. SQUIBB & SONS, INC. (US) 1994-06-07 — — US disclosed
US-5250691-A Heteroaryl derivatives of monocyclic beta-lactam antibiotics E. R. SQUIBB & SONS, INC. (US) 1993-10-05 — — US disclosed
EP-0531976-A1 Heteroaryl derivatives of monocyclic beta-lactam antibiotics E.R. SQUIBB & SONS, INC. (US) 1993-03-17 — — EP disclosed
EP-0420069-A2 Heterocyclic hydrazide derivatives of monocyclic beta-lactam antibiotics E.R. SQUIBB & SONS, INC. (US) 1991-04-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MEN1 1228/4885KMT2A 977/4885MAPT 4161/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET MEN1 1228/4885KMT2A 977/4885MAPT 4161/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MEN1 1228/4885KMT2A 977/4885MAPT 4161/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MEN1 1228/4885KMT2A 977/4885MAPT 4161/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET MEN1 1228/4885KMT2A 977/4885MAPT 4161/4885
US-20060199838-A1 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies IAPP, SNCA, BACE2 MEN1 3425/4885KMT2A 1592/4885MAPT 25/4885
US-20160185725-A1 c-Met Modulators and Method of Use FLT4, MET, FLT1 MEN1 1333/4885KMT2A 769/4885MAPT 4118/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET MEN1 1228/4885KMT2A 977/4885MAPT 4161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.